HIIFS
ARCT icon

Harel Insurance Investments & Financial Services’s Arcturus Therapeutics ARCT Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-800
Closed -$37K – 624
2020
Q2 		$37K Buy
+800
New +$27.6K ﹤0.01% 422

Other funds holding ARCT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Harel Insurance Investments & Financial Services's ARCT Position: Q3 2020 in Review

Harel Insurance Investments & Financial Services sold out of Arcturus Therapeutics (ARCT) in Q3 2020, closing a stake of 800 shares — an estimated $37K sold.

Harel Insurance Investments & Financial Services first reported a position in ARCT in Q2 2020 and held it in 1 quarter. The position peaked at $37K in Q2 2020. 127 funds tracked by Wall St. Rank hold ARCT as of Q3 2020.

  • Harel Insurance Investments & Financial Services reported no remaining Arcturus Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 800 Arcturus Therapeutics shares in Q3 2020, an estimated $37K.
  • Harel Insurance Investments & Financial Services first reported a position in Arcturus Therapeutics in Q2 2020 and held it in 1 quarter.
  • Harel Insurance Investments & Financial Services's Arcturus Therapeutics position peaked at $37K in Q2 2020.
  • 127 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2020.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q3 2020, filed 20 Oct 2020.